Germany Joins Decision To Suspend AZ Vaccine Over Safety, But Is It Really The Most ‘Cautious’ Approach?
Countries At Odds With EMA Guidance
AstraZeneca’s vaccine is under suspicion again, this time over safety, rather than efficacy, and the European Medicines Agency has promised a swift review.
You may also be interested in...
Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.